MCID: INT002
MIFTS: 61

Intermittent Claudication

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 12 54 43 15 37 71
Amyotrophic Lateral Sclerosis 71
Charcot's Syndrome 12
Charcot Disease 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
MeSH 43 D007383
SNOMED-CT 67 63491006
ICD10 32 I73.9
UMLS 71 C0002736 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to peripheral artery disease and angina pectoris, and has symptoms including seizures, tremor and polydipsia. An important gene associated with Intermittent Claudication is SELP (Selectin P), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Pioglitazone and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include Placenta, testes and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Charcot-Marie-Tooth disease (CMT) is one of the hereditary motor and sensory neuropathies of the... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 705)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.0 VWF VEGFA SELP IL6 IGF1 CRP
2 angina pectoris 31.6 IL6 CRP ACE
3 coronary heart disease 1 30.8 VWF SERPINE1 SELP IL6 CRP ACE
4 lipid metabolism disorder 30.8 SERPINE1 IL6 CRP ACE
5 carotid stenosis 30.8 VEGFA SELP CRP ACE
6 polyarteritis nodosa 30.8 SELP IL6 CRP
7 carotid artery disease 30.7 SELP CRP ACE
8 arteriosclerosis 30.7 SERPINE1 SERPINC1 SELP IL6 IL10 CRP
9 aortic aneurysm, familial abdominal, 1 30.6 IL6 CRP ACE
10 generalized atherosclerosis 30.6 VWF IL6 CRP ALB ACE
11 temporal arteritis 30.6 IL6 CRP CD40LG
12 thrombophilia due to thrombin defect 30.6 SERPINE1 SERPINC1 PF4 F2
13 raynaud disease 30.6 CRP CD40LG ACE
14 diarrhea 30.5 IL6 IL10 CD40LG ALB
15 systolic heart failure 30.4 VWF IL6 CRP ACE
16 protein s deficiency 30.4 SERPINE1 SERPINC1 F2
17 protein c deficiency 30.4 SERPINE1 SERPINC1 F2
18 peripheral vascular disease 30.4 VWF VEGFA SERPINE1 SERPINC1 SELP PF4
19 compartment syndrome 30.4 SERPINC1 IL6 F2 CRP ALB
20 polycythemia vera 30.3 VWF SELP PF4 F2
21 atherosclerosis susceptibility 30.2 VWF VEGFA SERPINE1 SELP IL6 CRP
22 common cold 30.2 SELP IL6 IL10 ALB
23 bone resorption disease 30.2 IL6 IGF1 CRP ALB
24 cerebrovascular disease 30.2 VWF SERPINE1 SELP IL6 F2 CRP
25 pulmonary tuberculosis 30.1 IL6 IL10 CRP ALB
26 thrombophilia due to activated protein c resistance 30.1 VWF SERPINE1 SERPINC1 PF4 F2
27 limb ischemia 30.1 VWF VEGFA TEK SERPINE1 PGF IL6
28 arteries, anomalies of 30.0 VWF VEGFA TNNT2 SERPINE1 SELP IL6
29 varicose veins 30.0 VWF VEGFA SERPINC1 IL6 F2
30 amyloidosis 30.0 TNNT2 IL6 CRP CD40LG ALB
31 vasculitis 30.0 VWF SELP IL6 CRP CD40LG
32 chlamydia pneumonia 30.0 IL6 IL10 CRP CD40LG
33 chlamydia 30.0 IL6 IL10 CRP CD40LG
34 coronary stenosis 30.0 VWF SERPINE1 IL6 CRP ALB ACE
35 hemangioma 30.0 VWF VEGFA TEK F2 ANGPT2
36 congestive heart failure 29.9 VEGFA TNNT2 IL6 CRP ANGPT2 ALB
37 thrombophilia 29.8 VWF SERPINE1 SERPINC1 SELP PF4 F2
38 glucose intolerance 29.8 SERPINE1 IL6 IGF1 CRP ALB ACE
39 deficiency anemia 29.8 SELP IL6 IGF1 CRP ALB ACE
40 scoliosis 29.6 VWF IL6 IGF1 ALB ACE
41 rheumatoid arthritis 29.6 VEGFA TEK IL6 IL10 CRP CD40LG
42 infective endocarditis 29.6 TNNT2 SERPINE1 PF4 IL6 F2 CRP
43 bronchitis 29.5 VEGFA IL6 IL10 CRP CD40LG ALB
44 glycogen storage disease 29.5 VWF IGF1 CRP ALB
45 thrombophlebitis 29.4 VWF SERPINE1 SERPINC1 SELP F2 CRP
46 thrombosis 29.4 VWF SERPINE1 SERPINC1 SELP PF4 F2
47 migraine with or without aura 1 29.3 IL6 HTR2A F2 CRP CD40LG ALB
48 intermediate coronary syndrome 29.3 VWF TNNT2 SERPINC1 SELP PF4 IL6
49 takayasu arteritis 29.2 VWF SERPINC1 IL6 IL10 F2 CRP
50 endocarditis 29.1 SERPINE1 SERPINC1 PF4 IL6 IL10 F2

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


seizures, tremor, polydipsia, fatigue, edema, back pain, pain, headache, syncope, cyanosis, chills, asthenia, chronic pain, sciatica, signs and symptoms, signs and symptoms, digestive, hot flushes, vertigo/dizziness, sleeplessness, signs and symptoms, respiratory, oral manifestations, eye manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACE ALB ANGPT2 CD40LG COL18A1 CRP
2 homeostasis/metabolism MP:0005376 10.47 ACE ALB ANGPT2 CD40LG COL18A1 CRP
3 immune system MP:0005387 10.35 ACE ALB ANGPT2 CD40LG CRP F2
4 hematopoietic system MP:0005397 10.32 ACE CD40LG F2 IGF1 IL10 IL6
5 mortality/aging MP:0010768 10.28 ACE ALB ANGPT2 CD40LG F2 IGF1
6 integument MP:0010771 10.16 ANGPT2 CD40LG F2 IGF1 IL10 IL6
7 digestive/alimentary MP:0005381 10.13 ALB ANGPT2 F2 HTR2A IL10 IL6
8 liver/biliary system MP:0005370 10.03 ACE ALB IL10 IL6 SELP SERPINC1
9 nervous system MP:0003631 10.03 CD40LG COL18A1 F2 IGF1 IL10 IL6
10 muscle MP:0005369 9.97 ALB HTR2A IGF1 IL10 IL6 TEK
11 neoplasm MP:0002006 9.97 ACE ALB COL18A1 IGF1 IL10 IL6
12 renal/urinary system MP:0005367 9.85 ACE ALB CD40LG COL18A1 IGF1 IL6
13 respiratory system MP:0005388 9.61 ANGPT2 F2 IGF1 IL10 IL6 PGF
14 vision/eye MP:0005391 9.28 ANGPT2 COL18A1 IL10 IL6 PGF SELP

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
5
Losartan Approved Phase 4 114798-26-4 3961
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
8
Glimepiride Approved Phase 4 93479-97-1 3476
9
Gliclazide Approved Phase 4 21187-98-4 3475
10
Glyburide Approved Phase 4 10238-21-8 3488
11
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
12
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
13
Allopurinol Approved Phase 4 315-30-0 2094
14
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
17
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
18
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
19
Ramipril Approved Phase 4 87333-19-5 5362129
20
Vorapaxar Approved Phase 4 618385-01-6
21
Thrombin Approved, Investigational Phase 4
22
Liraglutide Approved Phase 4 204656-20-2 44147092
23
Glucagon Approved Phase 4 16941-32-5
24
tannic acid Approved Phase 4 1401-55-4
25
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
26
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
27
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
28
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
29
Metformin Approved Phase 4 657-24-9 14219 4091
30
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
31
Candesartan Experimental Phase 4 139481-59-7 2541
32
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
33 Radiation-Protective Agents Phase 4
34 Anti-Inflammatory Agents Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antirheumatic Agents Phase 4
37 Tranquilizing Agents Phase 4
38 Anti-Anxiety Agents Phase 4
39 calcium channel blockers Phase 4
40 Calcium, Dietary Phase 4
41 Cyclooxygenase Inhibitors Phase 4
42 calcium heparin Phase 4
43 carnitine Phase 4
44 Cytochrome P-450 CYP3A Inducers Phase 4
45 Antipyretics Phase 4
46
protease inhibitors Phase 4
47 HIV Protease Inhibitors Phase 4
48 Nootropic Agents Phase 4
49 Angiotensin-Converting Enzyme Inhibitors Phase 4
50 Thyrotropin-Releasing Hormone Phase 4

Interventional clinical trials:

(show top 50) (show all 904)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
3 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
4 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
5 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
6 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
7 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
8 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex). Completed NCT00300690 Phase 4
9 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
10 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
11 A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication Completed NCT00887744 Phase 4
12 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
13 Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study Completed NCT00614926 Phase 4 Modafinil;Placebo
14 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
15 A Double Blind, Randomised, Placebo Controlled Trial to Study the Clinical and Cost Effectiveness of the Angiotensin Converting Enzyme Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
16 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
17 A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication Completed NCT00905359 Phase 4
18 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
19 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
20 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
21 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
22 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4
23 Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial Completed NCT00715416 Phase 4
24 4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
25 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
26 A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
27 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
28 Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. Completed NCT00431249 Phase 4 Cilostazol
29 Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery Completed NCT00281060 Phase 4
30 The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
31 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration Recruiting NCT04107740 Phase 4 C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo
32 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
33 Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease. Recruiting NCT02983214 Phase 4 Clopidogrel;Cilostazol
34 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Recruiting NCT02842424 Phase 4 Ramipril
35 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Active, not recruiting NCT01952457 Phase 4
36 Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study Not yet recruiting NCT04146155 Phase 4 Liraglutide+standard-of-care treatment
37 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Terminated NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
38 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
39 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
40 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo
41 Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR) Terminated NCT02374957 Phase 4 Cilostazol
42 A Clinical Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant in Comparison With the Best Non-operative Treatment of Lumbar Spine Stenosis Terminated NCT01057641 Phase 4
43 Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients Terminated NCT00517751 Phase 4
44 Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication Withdrawn NCT00558129 Phase 4
45 A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
46 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion. A Prospective Randomized Trial Comparing Silverhawk™ Atherectomy to CryoPlasty® Therapy for Lower Extremity Claudication Withdrawn NCT00407940 Phase 4
47 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
48 Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients Unknown status NCT00251849 Phase 3 Rifalazil
49 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
50 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 71 / NDF-RT 50 :


cilostazol
Pentoxifylline
Riluzole

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

40
Testes, Bone, Brain, Heart, Endothelial, Kidney, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 4877)
# Title Authors PMID Year
1
Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. 54 61
15649725 2005
2
Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. 54 61
15033248 2004
3
Platelet activation is increased in peripheral arterial disease. 54 61
12844097 2003
4
Platelets' glycoproteins and their ligands in patients with intermittent claudication. 54 61
12865882 2003
5
Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. 54 61
11958389 2001
6
Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. 54 61
11448424 2001
7
New treatment options in intermittent claudication: the US experience. 54 61
11355276 2001
8
Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. 54 61
11455059 2001
9
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. 54 61
11028477 2000
10
Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 54 61
9423790 1997
11
Repeated exercise induces release of soluble P-selectin in patients with intermittent claudication. 54 61
9408015 1997
12
Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. 54 61
1752890 1991
13
Metabolic-vascular coupling in skeletal muscle: A potential role for capillary pericytes? 61
31702069 2020
14
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers. 61
31181990 2020
15
Assessment of behavioral determinants influencing success of supervised exercise therapy in patients with intermittent claudication: A cross sectional survey. 61
31682890 2020
16
Two Cases of Popliteal Cystic Adventitial Disease Treated with Primary Stenting: Long-Term Results. 61
31622749 2020
17
Collapse of VBX balloon-expandable endoprosthesis in bilateral common iliac arteries in a lean, elderly patient with bent back. 61
32018024 2020
18
Antithrombotic therapy for postinterventional management of peripheral arterial disease. 61
31930282 2020
19
Mitochondrial DNA copy number is associated with all-cause mortality and cardiovascular events in patients with peripheral arterial disease. 61
32037598 2020
20
Test-retest reliability, agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. 61
31147129 2020
21
Relationship Between Cauda Equina Conduction Time and Type of Neurogenic Intermittent Claudication due to Lumbar Spinal Stenosis. 61
31335564 2020
22
Comparison of exercise oximetry and ankle pressure measurements for patients with intermittent claudication: an observational study of 433 patients. 61
31897737 2020
23
Long-term results after femoral thrombendarterectomy combined with simultaneous endovascular intervention in intermittent claudication and critical ischemia. 61
32002182 2020
24
Long-Term Mortality of Matched Patients with Intermittent Claudication Treated by High-Dose Paclitaxel-Coated Balloon Versus Plain Balloon Angioplasty: A Real-World Study. 61
31502025 2020
25
Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial. 61
31937137 2020
26
Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. 61
31926836 2020
27
Periodontal treatment and peripheral arterial disease severity - a retrospective analysis of health insurance claims data. 61
31983289 2020
28
Effects of Physical Exercise on the Expression of MicroRNAs: A Systematic Review. 61
31877120 2020
29
Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. 61
31606132 2020
30
Knowledge of peripheral artery disease: What do the public, healthcare practitioners, and trainees know? 61
32000617 2020
31
Low-Intensity Exercise Training Increases Heart Rate Variability in Patients With Peripheral Artery Disease. 61
31684758 2020
32
Effect of footplate neuromuscular electrical stimulation on functional and quality-of-life parameters in patients with peripheral artery disease: pilot, and subsequent randomized clinical trial. 61
31912491 2020
33
[Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review]. 61
31948540 2020
34
Effectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis: Two case reports. 61
31977898 2020
35
Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study. 61
31983287 2020
36
Cross-sectoral rehabilitation intervention for patients with intermittent claudication versus usual care for patients in non-operative management - the CIPIC Rehab Study: study protocol for a randomised controlled trial. 61
31964402 2020
37
Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. 61
31906705 2020
38
PTA and Stenting of Femoropopliteal Trunk With Cordis Smartflex Stent System: A Single-Center Experience. 61
31526118 2020
39
Factors Associated with Amputation after Peripheral Vascular Intervention for Intermittent Claudication. 61
31494265 2020
40
Leriche syndrome in a patient with acute pulmonary embolism and acute myocardial infarction: a case report and review of literature. 61
31952498 2020
41
Supervised Exercise Therapy for Intermittent Claudication. 61
31612216 2020
42
National survey of current practice and opinions on rehabilitation for intermittent claudication in the Danish Public Healthcare System. 61
31394936 2019
43
Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss. 61
31839346 2019
44
Drug coated balloon supported Supera stent versus Supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID Trial. 61
31603295 2019
45
Surgical Strategy to Reduce the Recurrence of Adventitial Cystic Disease after Treatment. 61
31915666 2019
46
Endovascular Treatment of Iliac Artery Stenosis Caused by Takayasu Arteritis: A 10-Year Experience. 61
31496339 2019
47
Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. 61
31870756 2019
48
Analysis of haemodynamics and angiogenic response to ischaemia in the obese type 2 diabetic model Spontaneously Diabetic Torii Leprfa (SDT fatty) rats. 61
31868944 2019
49
A systematic review of high-intensity interval training as an exercise intervention for intermittent claudication. 61
31257120 2019
50
Low Risk of Procedure Related Major Amputation Following Revascularisation for Intermittent Claudication: A Population Based Study. 61
31866238 2019

Variations for Intermittent Claudication

Copy number variations for Intermittent Claudication from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107025 17 11200000 22100000 Microduplication Charcot

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

Pathways related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 VEGFA TEK PGF PF4 IL6 IL10
2
Show member pathways
13.46 VEGFA TEK PGF IL6 IL10 IGF1
3
Show member pathways
13.3 TEK PGF PF4 IL6 IL10 IGF1
4
Show member pathways
13.14 TEK PGF PF4 IL6 IL10 IGF1
5
Show member pathways
12.97 VWF VEGFA TEK SERPINE1 SERPINC1 SELP
6
Show member pathways
12.81 VWF VEGFA TEK PGF IL6 IGF1
7 12.68 VEGFA TEK PGF IGF1 ANGPT2
8
Show member pathways
12.64 VEGFA TEK PGF IGF1 ANGPT2
9
Show member pathways
12.47 TEK IL6 IL10 F2 ANGPT2
10
Show member pathways
12.19 SERPINE1 IL6 F2 CRP ALB
11
Show member pathways
12.15 TNNT2 IL6 IGF1 ACE
12 12.07 VEGFA IL6 IL10 HTR2A
13
Show member pathways
12.05 TEK SELP PF4 F2 ANGPT2
14 11.99 VWF SERPINE1 SERPINC1 F2
15
Show member pathways
11.97 VWF SERPINE1 SERPINC1 PF4 F2
16 11.78 VEGFA TNNT2 IL6 IGF1 ALB
17 11.63 IL6 IL10 IGF1
18
Show member pathways
11.57 VEGFA IL6 CD40LG
19 11.56 SELP IL10 CD40LG
20 11.47 VEGFA TEK SERPINE1 IL6 IGF1 ANGPT2
21 11.42 VEGFA IL6 IGF1
22 11.32 SELP IL6 IL10 CD40LG
23 11.24 VEGFA SERPINE1 ANGPT2
24 10.18 TEK PGF PF4 IL6 IL10 IGF1

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 VWF VEGFA TEK SERPINE1 SERPINC1 PGF
2 collagen-containing extracellular matrix GO:0062023 9.73 VWF SERPINE1 SERPINC1 PF4 F2 COL18A1
3 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 IL6 F2 COL18A1 ALB
4 platelet alpha granule lumen GO:0031093 9.63 VWF VEGFA SERPINE1 PF4 IGF1 ALB
5 extracellular space GO:0005615 9.53 VEGFA SERPINE1 SERPINC1 SELP PGF PF4

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 VEGFA TEK PGF IL6 IL10 IGF1
2 positive regulation of gene expression GO:0010628 10.04 VEGFA PF4 IL6 IGF1 CRP
3 leukocyte migration GO:0050900 9.93 TEK SELP F2 ANGPT2
4 positive regulation of protein phosphorylation GO:0001934 9.92 VEGFA TEK PGF F2
5 cellular response to lipopolysaccharide GO:0071222 9.91 SERPINE1 PF4 IL6 IL10
6 inflammatory response GO:0006954 9.91 SELP PF4 IL6 IL10 CRP CD40LG
7 negative regulation of apoptotic process GO:0043066 9.91 VEGFA TEK IL6 IL10 IGF1 CD40LG
8 response to hypoxia GO:0001666 9.89 VEGFA TEK PGF ANGPT2
9 cellular protein metabolic process GO:0044267 9.88 SERPINC1 IL6 IGF1 F2 ALB
10 positive regulation of cell proliferation GO:0008284 9.87 VEGFA PGF IL6 IGF1 HTR2A F2
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 VEGFA IL6 IGF1
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 VEGFA IL6 IGF1 HTR2A
13 hemostasis GO:0007599 9.79 VWF SERPINC1 F2
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 TEK SELP IGF1 F2
15 acute-phase response GO:0006953 9.73 IL6 F2 CRP
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.72 TEK SERPINE1 IL10
17 positive regulation of endothelial cell proliferation GO:0001938 9.71 VEGFA TEK PGF IL10
18 sprouting angiogenesis GO:0002040 9.7 VEGFA TEK PGF
19 positive regulation of JAK-STAT cascade GO:0046427 9.69 IL6 IL10 F2
20 negative regulation of fibrinolysis GO:0051918 9.65 SERPINE1 F2
21 positive regulation of angiogenesis GO:0045766 9.65 VEGFA TEK SERPINE1 PGF ANGPT2
22 negative regulation of lipid storage GO:0010888 9.64 IL6 CRP
23 neutrophil mediated immunity GO:0002446 9.63 IL6 ACE
24 angiogenesis GO:0001525 9.63 VEGFA TEK SERPINE1 PGF COL18A1 ANGPT2
25 positive regulation of mast cell chemotaxis GO:0060754 9.61 VEGFA PGF
26 negative regulation of MHC class II biosynthetic process GO:0045347 9.58 PF4 IL10
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.58 VEGFA ACE
28 glomerulus vasculature development GO:0072012 9.57 TEK ANGPT2
29 Tie signaling pathway GO:0048014 9.54 TEK ANGPT2
30 platelet activation GO:0030168 9.35 VWF PF4 IL6 F2 CD40LG
31 platelet degranulation GO:0002576 9.17 VWF VEGFA SERPINE1 SELP PF4 IGF1

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 VWF VEGFA TNNT2 TEK SERPINE1 SERPINC1
2 cytokine activity GO:0005125 9.55 VEGFA PF4 IL6 IL10 CD40LG
3 drug binding GO:0008144 9.54 HTR2A ALB ACE
4 heparin binding GO:0008201 9.43 VEGFA SERPINC1 SELP PGF PF4 F2
5 vascular endothelial growth factor receptor binding GO:0005172 9.32 VEGFA PGF
6 growth factor activity GO:0008083 9.1 VEGFA PGF IL6 IL10 IGF1 F2

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....